Not Just a Formality? USPTO Sequence Rules May Impact Existing Biotech Portfolios

Not Just a Formality? USPTO Sequence Rules May Impact Existing Biotech Portfolios


Patent applications containing nucleic acid or protein sequences are required to include an electronic sequence listing using a required format and standard symbols. The United States Patent and Trademark Office , in conjunction with the World Intellectual Property Organization , is participating in an international effort that, if implemented, would dramatically change the requirements for sequence listings for the first time in 18 years.



from Biotech News